P01.031 VXM01 phase I study in patients with progressive glioblastoma - final results

Por Wick, W, Wick, A, Sahm, F, Riehl, D, von Deimling, A, Bendszus, M, Mickingereder, P, Beckhove, P, Schmitz Winnenthal, F, Jungk, C, Wieckoswski, S, Keller, A, Podola, L, Herold-Mende, C, Lubenau, H, Unterberg, A, Platten, M J
Publicado no Neuro Oncol (2018)

Preferential targeting of conserved Gag regions after vaccination with a heterologous DNA prime Modified Vaccinia Ankara boost HIV vaccine regime

Por Bauer, A, Podola, L, Haule, A, Sudi, L, Nilsson, C, Mann, P, Missanga, M, Kaluwa, B, Maboko, L, Lueer, C, Mwakatima, M, Aboud, S, Bakari, M, Currier, J, Robb, M, Joseph, S, McCormack, S, Lyamuya, E, Wahren, B, Sandström, E, Biberfeld, G, Hoelscher, M, Kroidl, A, Geldmacher, C
Publicado em 2012

Breadth, phenotype and functionality of Gag-specific T cell responses induced by a heterologous DNA/MVA prime-boost HIV-1 vaccine regimen

Por Podola, L, Bauer, A, Haule, A, Sudi, L, Nilsson, C, Godoy-Ramirez, K, Mann, P, Missanga, M, Kaluwa, B, Maboko, L, Lueer, C, Mwakatima, M, Aboud, S, Bakari, M, Currier, J, Robb, M, McCormack, S, Joseph, S, Lyamuya, E, Hoelscher, M, Wahren, B, Sandström, E, Biberfeld, G, Geldmacher, C, Kroidl, A
Publicado em 2012